entecavir / Generic mfg. - LARVOL DELTA

Long-term effectiveness of tenofovir alafenamide versus entecavir in treatment-naïve chronic hepatitis B: A REAL-B study. (PubMed, Am J Gastroenterol) - "BR rates were similar with ETV and TAF, while VR and CR were higher with TAF though the difference was modest (<5% overall, 7-9% in high HBV DNA or ALT groups). Antiviral selection between TAF vs. ETV should be based mainly on cost, side effect profile, and patient preference."

Journal • Hepatitis B • Infectious Disease • Inflammation

Long-term outcomes of a novel initial regimen: Rituximab plus pegylated interferon α-2b in untreated advanced indolent B-cell lymphoma – 5-year follow-up of the ripple study (ASH 2025) - P2 | "Induction therapy consisted of rituximab biosimilar (Henliritux®; 375mg/m² IV on day 1) plus Peg-IFN-α2b (Pegberon®; 135μg SC on days 1 and 8) every 21 days for 6 cycles.Responders received maintenance (rituximab every 8 weeks; Peg-IFN-α2b monthly) for ≤2 years. Rituximab biosimilar with Peg-IFN-α2b demonstrates durable efficacy and manageabletoxicity in treatment-naïve iBCL, particularly in FL and MALT subtypes. Absence of HBV reactivationsuggests potential synergism between Peg-IFN-α2b and entecavir in HBV suppression. These resultssupport further evaluation in larger randomized trials."

Metastases • B Cell Lymphoma • Extranodal Marginal Zone Lymphoma • Follicular Lymphoma • Hematological Disorders • Hematological Malignancies • Hepatitis B • Hepatitis C • Hepatology • Immune Modulation • Immunology • Indolent Lymphoma • Infectious Disease • Lymphoma • Lymphoplasmacytic Lymphoma • Marginal Zone Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Small Lymphocytic Lymphoma • Thrombocytopenia • Waldenstrom Macroglobulinemia • IFNA1

Concurrent use of nucleoside reverse transcriptase inhibitors and purine analogs is associated with worse survival for patients with myeloid neoplasms: A single-center retrospective analysis (ASH 2025) - "Statistical analysis included descriptive analysis, Kaplan-Meier modeling, andmultivariable analyses for event-free survival (EFS) and overall survival (OS), with the multivariableanalysis constructed using treatment-related mortality (TRM) score. In this cohort, 21 patients (30%) were treated with both a purine analog (17 with cladribine, 4fludarabine) and an NRTI (9 with entecavir, 6 emtricitabine/tenofovir, 4 lamivudine, 2 tenofovirmonotherapy), with 13 of these patients receiving the purine analog for induction therapy. Amongst the38 patients who did not have the drug-drug interaction, for induction therapy, 22 (58%) receivedcladribine, cytarabine, G-CSF, and mitoxantrone (CLAG-M), 10 (26%) received a hypomethylating agent, 5(13%) received cytarabine and an anthracycline (7+3), and 2 (5%) received fludarabine, cytarabine, G-CSF,and idarubicin (FLAG-IDA)... Among patients with high-grade myeloid disease and HIV+ or HBV+ infection, concomitanttherapy with purine..."

Retrospective data • Acute Myelogenous Leukemia • Hematological Malignancies • Hepatitis B • Hepatology • Human Immunodeficiency Virus • Infectious Disease • Leukemia • Myelodysplastic Syndrome • CD4

VALIDATION OF THE PAGE-B SCORE AS A PROGNOSIS OF DEVELOPMENT TO HEPATOCELLULAR CARCINOMA (HCC) IN CHRONIC HEPATITIS B, IN THE BRAZILIAN POPULATION. (PubMed, Arq Gastroenterol) - "The PAGE-B score demonstrated, in the Brazilian population, a performance similar to that observed in studies with European and Asian populations in terms of sensitivity, specificity, and predictive values for HCC prediction. Based on these results, the PAGE-B score can be used in the Brazilian population to predict the risk of HCC."

Journal • Observational data • Retrospective data • Fibrosis • Gastroenterology • Hepatitis B • Hepatocellular Cancer • Hepatology • Immunology • Infectious Disease • Liver Cirrhosis • Oncology • Solid Tumor

Efficacy and safety of entecavir, peginterferon alfa-2b and GM-CSF combination therapy: the anchor randomized controlled trial. (PubMed, Hepatol Int) - P3 | "In virally suppressed patients with HBsAg level < 3000 IU/mL, ETV plus Peg-IFN significantly increased HBsAg loss and HBsAg seroconversion, whereas adding GM-CSF conferred no additional efficacy benefit. Age, early on-treatment HBsAg level and 24-week HBV RNA decline correlated with HBsAg loss. This trial is registered at ClinicalTrials.gov, NCT02327416."

Journal • Hepatitis B • Infectious Disease • Inflammation • CSF2

Monitoring adherence and renal safety of nucleos(t)ide analogues for patients with chronic hepatitis B. (PubMed, Clin Transl Gastroenterol) - "In this real-world cohort, adherence to recommended monitoring for CHB patients on NAs was suboptimal. ETV, TDF and TAF demonstrated comparable renal safety profiles over 3 years."

Journal • Fibrosis • Hepatitis B • Immunology • Infectious Disease • Inflammation • Nephrology • Renal Disease

A Prospective Study to Evaluate the Efficacy and Safety of Entecavir ODT Conversion in Stable Liver Transplant Patients (clinicaltrials.gov) - P2 | N=82 | Not yet recruiting | Sponsor: Jongman Kim

New P2 trial • Hepatitis B • Infectious Disease • Inflammation • Transplantation • CST3

Clinical treatment outcomes of chronic hepatitis B pediatric with coexistence of HBeAg and HBeAb. (PubMed, Scand J Gastroenterol) - "This study assessed antiviral efficacy and predictors of functional cure in HBeAg/HBeAb-positive children/adolescents treated with PEG-IFNα-2a or entecavir (ETV)...ETV was more effective for short-term viral suppression and hepatic inflammation reduction, while PEG-IFNα-2a promoted HBsAg decline and functional cure. Younger age and early qHBsAg levels were key predictors of treatment success."

Journal • Hepatitis B • Infectious Disease • Inflammation • Pediatrics • IFNA1

Different nucleos(t)ide analogs in resected hepatitis B virus-associated hepatocellular carcinoma: a systematic review. (PubMed, Front Pharmacol) - "Compared with the control group, antiviral therapies using telbivudine (HR [95% CrI] = 0.23 [0.12,0.44]), tenofovir disoproxil fumarate (HR [95% CrI] = 0.40 [0.30,0.52]), lamivudine (HR [95% CrI] = 0.50 [0.34, 0.75]), adefovir (HR [95% CrI] = 0.55 [0.38,0.79]), and entecavir (HR [95% CrI] = 0.55 [0.43,0.71]) significantly improved OS...When compared to other nucleos(t)ide analogs, telbivudine and tenofovir disoproxil fumarate exhibited the most notable effects. Identifier CRD42024612794."

Journal • Review • Hepatitis B • Hepatocellular Cancer • Infectious Disease • Oncology • Solid Tumor

TAF Monotherapy Versus ETV Combined With TAF on the Efficacy and Prognosis of Immunotherapy for Hepatitis B-Related Hepatocellular Carcinoma (clinicaltrials.gov) - P=N/A | N=120 | Not yet recruiting | Sponsor: Sun Yat-sen University

Monotherapy • New trial • Hepatitis B • Hepatocellular Cancer • Infectious Disease • Oncology • Solid Tumor

AND Logic Gate-Based Dual-Specificity DNA Circuit for Isothermal HBV rcDNA Detection. (PubMed, JACS Au) - "Yet the HBV genome exhibits complex variation, such as multiple-site mutations for entecavir resistance, closely adjacent mutation loci, and the need to distinguish missense from nonsense mutations due to genetic code degeneracy and amino acid mutation conservatism, creating challenges for detection specificity and mutation identification...By this DNA circuit, we achieved enhanced sensitivity (limit of detection: 29.11 fM) and high specificity to discriminate adjacent single-base mismatches with excellent performance in clinical samples. We envision that this innovative and convenient assay advances point-of-care HBV DNA testing."

Journal • Hepatitis B • Infectious Disease • Inflammation

Evaluation of the Efficacy of Tenofovir Alafenamide in Patients with Low-Level Viremia Under Chronic Hepatitis B Treatment. (PubMed, Viruses) - "In this multicenter, retrospective study involving 62 patients, we investigated whether switching from entecavir (ETV) or tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) represents a superior treatment strategy for patients with chronic hepatitis B (CHB) experiencing low-level viremia (LLV). This evidence suggests that TAF provides robust virological control in LLV patients and is associated with favorable biochemical improvements. However, due to the study's limitations, the strong assertion that TAF promotes the regression of liver fibrosis and reduces the risk of hepatocellular carcinoma (HCC) must be interpreted with caution."

Journal • Retrospective data • Fibrosis • Hepatitis B • Hepatocellular Cancer • Immunology • Infectious Disease • Inflammation • Liver Cirrhosis • Oncology • Solid Tumor

Real-World Effectiveness of Antiviral Prophylaxis for Preventing Hepatitis B Virus (HBV) Reactivation in Patients Undergoing Immunosuppressive Therapy. (PubMed, Viruses) - "Prophylaxis consisted of entecavir in 76.4%, tenofovir alafenamide in 13.1%, and tenofovir disoproxil fumarate in 10.5%. HBV reactivation occurred in only one patient, who had discontinued treatment. These findings emphasize the importance of HBV screening and timely prophylactic antiviral therapy in patients undergoing immunosuppression to effectively prevent HBV reactivation."

Journal • Real-world evidence • Retrospective data • Hepatitis B • Infectious Disease • Inflammation

Navigating the Latest Hepatitis B Virus Reactivation Guidelines. (PubMed, Diseases) - "Entecavir (ETV), tenofovir disoproxil fumarate (TDF), and tenofovir alafenamide (TAF) are all highly effective in preventing HBV reactivation during immunosuppression and all are considered to be economically viable options for HBVr high risk patients. When selecting among these agents, safety considerations-particularly renal and bone toxicity-and insurance coverage remain the primary factors directing clinical decision-making."

Journal • Review • Hepatitis B • Infectious Disease • Inflammation • Transplantation

Effect of antiviral therapy on 3-year recurrence and prognosis of hepatocellular carcinoma after curative radiofrequency ablation. (PubMed, World J Gastrointest Oncol) - "Among patients with hepatitis B cirrhosis-related HCC, TDF and TAF are associated with lower 2-year and 3-year HCC recurrence rates after curative RFA treatment compared with ETV. However, there were no significant differences in 3-year mortality rates between the ETV, TDF, and TAF groups."

Journal • Fibrosis • Hepatitis B • Hepatocellular Cancer • Immunology • Infectious Disease • Liver Cancer • Oncology • Solid Tumor • AFP

Serum type III procollagen, procollagen V, tumour necrosis factor-a, interleukin-6 in liver cirrhosis after antiviral treatment. (PubMed, J Med Biochem) - "Group B showed a higher effective treatment rate (97.82%) compared to group A (76.08%). Malnutrition improved significantly more in group B. After treatment, group B exhibited more significant reductions in BMI, TSF, AMC, PA, Hb, ALB, TNF-a, CRP, IL-6, TBIL, AST, ALT, HA, PCIII, and IVC than group A. Entecavir combined with reduced glutathione improves liver function and nutritional status and reduces inflammatory markers in patients with hepatitis B and alcoholic liver cirrhosis, demonstrating high safety and effectiveness."

Journal • Addiction (Opioid and Alcohol) • Fibrosis • Gastroenterology • Hepatitis B • Hepatology • Immunology • Infectious Disease • Liver Cirrhosis • Oncology • IL6 • TNFA

A Study of ALG-000184 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single and Multiple Doses in Healthy Volunteers and CHB Subjects (clinicaltrials.gov) - P1 | N=165 | Completed | Sponsor: Aligos Therapeutics | Active, not recruiting ➔ Completed

First-in-human • Trial completion • Hepatitis B • Infectious Disease • Inflammation

CLEAR-HBV: Combined Light, ExVivo, and Antivirals for Recipients of Lungs From HBV Donors (clinicaltrials.gov) - P4 | N=20 | Recruiting | Sponsor: University Health Network, Toronto | Not yet recruiting ➔ Recruiting

Enrollment open • Hepatitis B • Infectious Disease • Inflammation • Transplantation

Glofitamab in Aggressive B Non-Hodgkin Lymphoma (B-NHL): A Real World Experience (ASH 2023) - "Glofitamab was administered according to the published protocol, with obinutuzumab given on the first day to mitigate the severity of cytokine release syndrome (CRS). Patients with occult HBV infection were given antiviral prophylaxis with entecavir...ConclusionGlofitamab showed similar efficacy in real-world patients compared with published results. It was safe in patients with occult HBV infection given antiviral prophylaxis."

Clinical • Real-world • Real-world evidence • Anemia • B Cell Lymphoma • CNS Lymphoma • Cytomegalovirus Infection • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Genetic Disorders • Hematological Disorders • Hematological Malignancies • Hepatitis B • Hepatology • High-grade B-cell lymphoma • Infectious Disease • Lymphoma • Marginal Zone Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Ocular Inflammation • Oncology • Ophthalmology • Retinal Disorders • Thrombocytopenia

Novel Chemotherapy-Free Initial Treatment of Rituximab Biosimilar Plus Pegylated Interferon α-2b in Pts with Untreated Advanced Indolent B-Cell Non-Hodgkin's Lymphoma: Results of the Ripple 3-Year Follow-up Study (ASH 2023) - P2 | "During induction phase, pts received rituximab biosimilar (Henliritux® Shanghai Henlius Biotech) 375 mg/m2 intravenous infusion on d1. Peg-IFN-α2b (Pegberon®, Xiamen Amoytop Biotech) was given at a dose of 135ug, subcutaneously, on d1,8...Simultaneously, CHB pts orally treated with entecavir continuously... Rituximab biosimilar plus pegylated interferon α-2b provided favorable response in newly diagnosed advanced iBCL with mild toxicity. No hepatitis B virus reactivation was observed."

Clinical • Metastases • Anemia • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Fatigue • Follicular Lymphoma • Hematological Malignancies • Hepatitis B • Hepatology • Indolent Lymphoma • Infectious Disease • Lymphoma • Lymphoplasmacytic Lymphoma • Marginal Zone Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Small Lymphocytic Lymphoma • Thrombocytopenia • Waldenstrom Macroglobulinemia • IFNA1

Recurrence of HBV Reactivation after Allogeneic Hematopoietic Transplantation in Recipients with Resolved HBV Infection: A Nation-Wide Multicenter Retrospective Study (ASH 2023) - "All patients received preemptive NA (entecavir 65, tenofovir alafenamide 6, tenofovir 1). Careful monitoring of HBV-DNA is important even after the discontinuation of NA in the case with HBV reactivation after allo-HSCT because multiple reactivations could occur. A prospective randomized trial of the HB vaccine after allo-HSCT for preventing HBV reactivation is now ongoing (UMIN000034113)."

Retrospective data • Acute Graft versus Host Disease • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Adult T-Cell Leukemia-Lymphoma • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Chronic Myeloid Leukemia • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Hepatitis B • Hepatology • Immunology • Infectious Disease • Leukemia • Lymphoma • Myelodysplastic Syndrome • Non-Hodgkin’s Lymphoma • Oncology • Transplantation

Hepatitis B Reactivation without Hepatitis Is a Common Event in Adolescent/Adult Patients of Acute Lymphoblastic Leukemia with Occult Hepatitis B (OHBI) Treated on Pediatric Protocols and Warrants Prophylactic Antivirals: A Prospective Cohort Study (ASH 2023) - "All of these patients were started on antivirals (Entecavir)... We conclude that the risk of HBV reactivation is significant in adolescent/adult ALL patients with OHBI treated on pediatric inspired ALL protocols. HBV related hepatitis is a late event, and monitoring with liver function tests alone is not sufficient. The use of prophylactic antivirals is justified in patients with ALL."

Clinical • Acute Lymphocytic Leukemia • Hematological Malignancies • Hepatitis B • Hepatitis C • Hepatology • Human Immunodeficiency Virus • Infectious Disease • Inflammation • Leukemia • Oncology • Pediatrics

Machine Learning-Based Prediction of Decompensation in Hepatitis B Virus-Related Cirrhosis. (PubMed, Diagnostics (Basel)) - "The use of two antiviral drugs were considered: entecavir (ETV) and lamivudine (LAM)... ML-based prediction of decompensation using electronic health records may assist clinicians in decision making. Findings of this study also underline the impact of antiviral therapy as a key predictor for decompensation."

Journal • Fibrosis • Hepatitis B • Immunology • Infectious Disease • Inflammation • Liver Cirrhosis

Inhibiting silencing information regulator 1 is conducive to the suppression of hepatitis B virus replication by entecavir. (PubMed, J Pharmacol Exp Ther) - "In this study, we first probed into the effect of sirtuin 1 inhibitor III (EX527) on hepatitis B virus (HBV) replication following inhibition of silencing information regulator 1 (SIRT1) and whether EX527 can enhance the efficacy of entecavir (ETV) in anti-HBV therapy. SIGNIFICANCE STATEMENT: This study has important theoretical and practical significance. It explores the factors influencing the replication of the hepatitis B virus from a new perspective and provides new ideas for follow-up research."

Journal • Hepatitis B • Infectious Disease • Inflammation • Oncology • IL6 • TNFA

Successful Antiviral Treatment of Hepatitis C Virus-Associated Polyarteritis Nodosa with Resolution of Dialysis-Dependent Kidney Failure (KIDNEY WEEK 2025) - "Thrice weekly HD was commenced, 60 mg prednisolone daily with gradual weaning, glecaprevir + pibrentasvir thrice daily for 23 weeks, and entecavir 0.5 mg once weekly for prevention of HBV reactivation. Discussion This is the first report of HCV-associated PAN requiring dialysis treated with glecaprevir + pibrentasvir that was able to successfully discontinue HD and achieve vasculitis remission following complete resolution of HCV viremia. The patient now has stage 3 CKD and remains on a SGLT2 inhibitor."

Cardiovascular • Chronic Kidney Disease • Hepatitis B • Hepatitis C • Hepatology • Human Immunodeficiency Virus • Hypertension • Immunology • Infectious Disease • Inflammation • Inflammatory Arthritis • Rare Diseases • Renal Disease • Vasculitis